β-blockers in congestive heart failure. A bayesian meta-analysis

Annals of Internal Medicine

Volumn 134, Issue 7, 2001, Pages 550-560

  Brophy, J M ^a   Joseph, L ^a   Rouleau, J L ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; NEBIVOLOL; PLACEBO;

ARTICLE; BAYES THEOREM; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DATA BASE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROBABILITY;

EID: 0035799381     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-7-200104030-00008     Document Type: Article

References (54)

1. Epidemiology of congestive heart failure
2. Epidemiology of congestive heart failure: Canadian data from 1970 to 1989
3. The epidemiology of heart failure
4. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence
5. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
6. Hospital care for elderly patients with diseases of the circulatory system. A comparison of hospital use in the United States and Canada
7. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
8. The effect of digoxin on mortality and morbidity in patients with heart failure
9. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure
10. Effect of oral milrinone on mortality in severe chronic heart failure
11. Effect of flosequinin on survival in chronic heart failure: Preliminary results of the PROFILE study
12. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
13. Beta-blocker therapy for congestive heart failure: A systemic overview and critical appraisal of the published trials
14. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials
15. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials
16. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
18. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
19. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy
20. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial
21. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
22. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy
23. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
24. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
25. A randomized trial of beta-blockade in heart failure
26. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
27. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy
28. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
29. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
30. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise
31. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
32. Safety and efficacy of carvedilol in severe heart failure
33. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
34. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study
35. Usefulness of bucindolol in congestive heart failure
36. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy
37. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure
38. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study
39. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
40. Beta adrenergic blockers and survival in heart failure
41. Discrepancies between meta-analyses and subsequent large randomized, controlled trials
42. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol
43. Xamoterol in severe heart failure
44. Toward evidence-based medical statistics. 1. The P value fallacy
45. Toward evidence-based medical statistics. 2: The Bayes factor
46. Clinical trials and statistical verdicts: Probable grounds for appeal
47. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
48. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?
49. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes
50. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project